Comprehensive and quantitative urinary metabolomic profiling for improved characterization of diabetic nephropathy.

INTRODUCTION

Diabetic nephropathy (DN) is a major cause of chronic kidney disease and end-stage renal failure worldwide. The current diagnostic marker, albuminuria, lacks specificity and often detects renal damage only at advanced stages.

OBJECTIVES

This study aimed to characterize urinary metabolic alterations associated with DN and explore metabolite panels with diagnostic potential.

METHODS

A targeted urinary metabolomics analysis was performed using the validated TMIC Urine MEGA Assay, quantifying 268 metabolites in 60 participants (20 controls, 20 type 2 diabetes mellitus [DM-2], and 20 DN patients). Data were analyzed by Partial Least Squares Discriminant Analysis (PLS-DA) for visualization, and penalized regression algorithms [Least Absolute Shrinkage and Selection Operator (LASSO) and Elastic Net (EN) with a Genetic Algorithm (GA)] followed by logistic regression (LR) modeling to identify potential discriminative variables.

RESULTS

DN patients showed marked alterations in metabolites related to oxidative stress, mitochondrial dysfunction, and inflammation. Twenty-four of 86 quantified uremic toxins differed significantly between DN and comparison groups. The LASSO-derived model identified β-alanine, kynurenine, glucose and argininic acid as key discriminants (AUC = 0.905, 10-fold CV), while inclusion of GFR and additional metabolites (2-hydroxybutyric acid, shikimic acid) improved performance (AUC = 0.96).

CONCLUSIONS

Quantitative urinary metabolomics revealed metabolic perturbations reflective of DN pathophysiology and identified candidate metabolite panels with potential for non-invasive disease characterization. These findings, though preliminary, provide a foundation for validation in larger, longitudinal cohorts and for integrating urinary metabolomics into precision diagnostics for diabetic kidney disease.